Li Mengna, Liu Xintong, Chen Weijian, Xu Haoyue, Huang Fang, Yao Qingbo, Jia Xiangze, Huang Yanyan
Guangdong Provincial Key Laboratory of Intelligent Food Manufacturing, College of Food Science and Engineering, Foshan University, Foshan 528225, China.
School of Food Sciences and Engineering, South China University of Technology, Guangzhou 510640, China.
Microorganisms. 2025 Apr 7;13(4):840. doi: 10.3390/microorganisms13040840.
The pathogenesis of ulcerative colitis (UC) has been fundamentally associated with intestinal microbiota dysbiosis and disruption of immune homeostasis. This study systematically investigates the therapeutic potential of HYY-S10 (HYY-S10), a novel strain isolated from De'ang sour tea in Yun an, China, with a focus on its mechanisms for alleviating colitis through the modulation of gut microbiota. Using a dextran sulfate sodium (DSS)-induced colitis model in C57BL/6J mice, our findings demonstrated that seven days of oral supplementation with HYY-S10 (1 × 10 CFU/mL, 0.2 mL/10 g body weight) significantly improved Disease Activity Index (DAI) scores and attenuated characteristic colitis symptoms, including progressive weight loss, rectal bleeding, and abnormal stool consistency. Administration of HYY-S10 exhibited significant immunomodulatory effects characterized by the downregulation of pro-inflammatory mediators (such as IL-1β, IL-6, IFN-γ, and LPS) while concomitantly upregulating anti-inflammatory IL-10 expression. Additionally, the strain enhanced intestinal antioxidant capacity by increasing GSH-Px activity, which collectively contributed to the reduction in intestinal inflammation. Furthermore, HYY-S10 demonstrated multifaceted protective effects by ameliorating oxidative stress through the restoration of redox homeostasis and modulation of gut microbial ecology. Probiotic intervention significantly increased short-chain fatty acids (SCFAs) production and notably enhanced the relative abundance of beneficial taxa, including and _B, while restoring microbial diversity and ecological stability. Collectively, our results demonstrate that HYY-S10 alleviates experimental colitis by modulating the intestinal immune axis and microbiota composition, providing mechanistic insights to support its potential as a probiotic-based therapeutic strategy for UC.
溃疡性结肠炎（UC）的发病机制与肠道微生物群失调和免疫稳态破坏密切相关。本研究系统地探究了从中国云南德昂酸茶中分离出的新型菌株HYY-S10的治疗潜力，重点关注其通过调节肠道微生物群缓解结肠炎的机制。在C57BL/6J小鼠中使用葡聚糖硫酸钠（DSS）诱导的结肠炎模型，我们的研究结果表明，连续七天口服补充HYY-S10（1×10 CFU/mL，0.2 mL/10 g体重）可显著改善疾病活动指数（DAI）评分，并减轻特征性结肠炎症状，包括体重逐渐减轻、直肠出血和粪便稠度异常。给予HYY-S10表现出显著的免疫调节作用，其特征是下调促炎介质（如IL-1β、IL-6、IFN-γ和LPS），同时上调抗炎性IL-10的表达。此外，该菌株通过增加谷胱甘肽过氧化物酶（GSH-Px）活性增强肠道抗氧化能力，共同促进肠道炎症的减轻。此外，HYY-S10通过恢复氧化还原稳态和调节肠道微生物生态来改善氧化应激，从而发挥多方面的保护作用。益生菌干预显著增加了短链脂肪酸（SCFAs）的产生，并显著提高了有益类群的相对丰度，包括 和_B，同时恢复了微生物多样性和生态稳定性。总的来说，我们的结果表明，HYY-S10通过调节肠道免疫轴和微生物群组成来减轻实验性结肠炎，为支持其作为基于益生菌的UC治疗策略的潜力提供了机制性见解。
